12 results about "Receptor type" patented technology

Compositions and methods for editing, e.g., altering, DNA sequences within TGFβR2 are provided. Compositions and methods for reducing or eliminating TGFβR2 protein expression in a cell are provided. Compositions and methods for immunotherapy are provided.

Provided in the present invention are an siRNA for inhibiting the expression of the activin A receptor type 1C (ACVR1C) gene, and a conjugate thereof. The siRNA comprises a sense strand and an antisense strand. The antisense strand comprises at least 17 consecutive nucleotides that differ from nucleotide sequences set forth in SEQ ID NO: 1236-SEQ ID NO: 2470 by no more than 4 nucleotides. The antisense strand is 17-30 nucleotides in length; and the sense strand is 17-30 nucleotides in length, and is at least partially or completely complementary to the antisense strand. The siRNA, siRNA conjugate and pharmaceutical composition provided in the present invention exhibit good stability, great ACVR1C gene inhibitory activity, and satisfactory cytotoxicity and immunostimulatory activity.

The present disclosure provides methods and compositions for reducing the addictive liability of opioid analgesics in a subject, for example, by co-administering to the subject the opioid and a serotonin receptor type 2 (5HT2) agonist or a serotonin (5HT) releasing agent. The disclosed methods include methods for preventing opioid abuse, methods for reducing the rewarding effect of an opioid, methods for reducing the addictive liability of an opioid, methods for eliminating or substantially reducing the tendency for a subject to develop physical dependence, tolerance, and / or withdrawal symptoms with respect to an opioid, and methods for eliminating or substantially reducing the tendency for a subject to use opioids in ways not prescribed, take opioids more often or in larger amounts than prescribed, and / or use opioids recreationally. The methods can be performed on a subject, such as a patient (e.g., a human patient).

The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and / or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent.

The present invention relates to new compounds of formula (1):as modulators of serotonin receptor 1B (5-HTR1B) also known as 5-hydroxytryptamine receptor 1B (5-HT1B). The compounds are of potential utility in the treatment of diseases and conditions mediated by serotonin receptor type 1B (5-HTR1B), such as cancer, including blood cancer and solid tumors, respiratory diseases and hepatic disorders.

The invention relates to a novel epitope of PTPRZ1 which presents good immunogenicity and is useful for immunotherapy of cancer.

The present disclosure provides a culture medium for cell culturing, the culture medium containing a combination of specific components. The present disclosure provides a culture medium which contains a combination of components selected from the group consisting of: (1) a halcinonide component; (2) an ALK4 / 7 inhibitor or a TGFβ receptor type-1 kinase inhibitor; (3) a BRD7 / 9 double degradation factor or a BRD7 / 9 binding molecule (degradation factor); (4) an LATS1 / 2 inhibitor, a PKA inhibitor, or an AKT1 inhibitor; (5) a CK1 / 2 inhibitor, an insulin receptor inhibitor, a Tyr kinase inhibitor, a PKA inhibitor or a PKC inhibitor, or an adenosine kinase inhibitor; (6) an E-selectin inhibitor, a VCAM1 inhibitor, or an ICAM1 inhibitor; and (7) an LATS1 inhibitor + an LATS2 inhibitor.

Device (1) for determining a combined anesthetic effect on a patient anesthetized by means of a combination of at least two active substances characterized in that the device is set up to perform the following steps: Determining the concentration of each active ingredient at the site of action using pharmacokinetic and / or pharmacodynamic models; Summarizing the effect of all active ingredients within each class of active ingredients used, whereby the potency of the active ingredients is added if they act on the same receptor type; Determining the synergistic interaction between at least two active substances used in anesthesia by determining a combined potency N of the anesthetic effect of the applied active substances, based on a mean anesthetic efficacy of the active substances used and an interaction term. determining an NSRI index value NSRI = 100 ∗ ( 1 − ( N / N ' ) sl 1 + ( N / N ' ) sl ) , where - N is the combined power, - N' is a specific value at which an NSRI value of 50% is reached. - and sl is a slope factor for a transformation from N to NSRI; Display of the NSRI index value using a display device (29); and Display of at least one comparative value (67, 69) for anesthesia management and / or patient arousal by means of the display device (29).

This specification provides a method for using compounds that bind to interleukin-1 beta (IL-1β) in the interleukin-1 beta (IL-1β) binding pocket identified herein, thereby capturing IL-1β and inhibiting its interaction with the interleukin-1 receptor type I (IL-1R1).